For: | Nashawi M, Ahmed MS, Amin T, Abualfoul M, Chilton R. Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy. World J Cardiol 2021; 13(12): 676-694 [PMID: 35070111 DOI: 10.4330/wjc.v13.i12.676] |
---|---|
URL: | https://www.wjgnet.com/1949-8462/full/v13/i12/676.htm |
Number | Citing Articles |
1 |
Tadesse M. Abegaz, Ahmead Baljoon, Oluwaseun Kilanko, Fatimah Sherbeny, Askal Ayalew Ali. Machine learning algorithms to predict major adverse cardiovascular events in patients with diabetes. Computers in Biology and Medicine 2023; 164: 107289 doi: 10.1016/j.compbiomed.2023.107289
|
2 |
Lucia Scisciola, Vittoria Cataldo, Fatemeh Taktaz, Rosaria Anna Fontanella, Ada Pesapane, Puja Ghosh, Martina Franzese, Armando Puocci, Antonella De Angelis, Liberata Sportiello, Raffaele Marfella, Michelangela Barbieri. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Frontiers in Cardiovascular Medicine 2022; 9 doi: 10.3389/fcvm.2022.1008922
|